Type 2 Diabetes Mellitus
Conditions
Keywords
Automated Insulin Delivery, T2D, Type 2 Diabetes, Omnipod, AID, Fully closed loop, FCL
Brief summary
A multi-center, 26-week randomized controlled trial (RCT) to evaluate the safety and efficacy of the fully closed loop Omnipod M System in adults with type 2 diabetes using basal/bolus insulin therapy or basal-only insulin therapy, with the primary endpoint after 15 weeks and secondary analysis at 26 weeks; followed by an extension phase after completion of the 26-week trial where the Intervention group will continue to use Omnipod M and the Control group will crossover to use Omnipod M for 26 weeks
Interventions
DEVICEDevice: Omnipod M System with study CGM
The Omnipod M system with the study CGM
DEVICEStandard Therapy plus study CGM
Standard therapy is continuation of pre-study insulin regimen and study CGM.
Sponsors
Insulet Corporation
Jaeb Center for Health Research
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age at time of consent 18-75 years (inclusive) 2. Clinical diagnosis, based on investigator assessment, of type 2 diabetes for at least 6 months at time of screening 3. On insulin therapy for at least 3 months at time of screening, with no change to insulin regimen for 6 weeks prior (AID use within past 3 months excluded) to initiating baseline CGM data collection. * Regimen is defined as (1) Basal-bolus insulin therapy (a) using multiple daily injections of insulin (MDI), (b) non-automated insulin pump, or (c) MDI with premix insulin; or (2) basal insulin only (without bolus insulin). * Basal-bolus insulin therapy defined as use of a basal insulin (either long-acting or intermediate-acting (e.g., NPH) plus at least one mealtime insulin dose per day, or a non-automated insulin pump * Inhaled insulin may be used in addition to or instead of mealtime injections pre-study and as part of the Control group 4. For basal only users, screening A1C ≥7.5% and \<14.0%. For basal bolus users (i.e., all others), screening A1C ≥6.0% and \<14.0%. • A1C measurement within 28 days prior to enrollment is acceptable 5. Willing to use only the following types of U-100 insulin while using the study pump: Humalog, Novolog, Admelog, Kirsty, Fiasp, Lyumjev or their generic/biosimilar equivalents 6. Willing to use only study-provided Libre 2 Plus or 3 Plus sensor during the study and not use another sensor 7. Deemed appropriate for pump therapy per Investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities 8. No anticipated need to newly initiate noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications that have a glucose lowering effect during the 26-week RCT phase. (Additions or changes in these medications will be permitted during the Extension Phase) 9. If using noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications that have a glucose-lowering effect, prescribed dose has been stable for 6 weeks prior to baseline CGM collection; and there is not an anticipated need to increase the dose during the 26-week trial phase (dose reductions will be permitted for safety). 10. Investigator has confidence that the participant can safely operate all study devices and can adhere to the protocol 11. Willing to wear the system, including Pods, continuously throughout the 26-week trial phase 12. Willing and able to sign the Informed Consent Form (ICF) 13. Able to read and understand English 14. If of childbearing potential, willing and able to have pregnancy testing
Exclusion criteria
1. Use of an automated insulin delivery pump within 3 months prior to screening 2. Any medical condition, which in the opinion of the Investigator, would put the participant at an unacceptable safety risk. This may include untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, unstable proliferative retinopathy, unstable psychiatric conditions such as eating disorders, drug or alcohol abuse. 3. Current or known history of coronary artery disease that is not stable with medical management in the opinion of the investigator, including unstable angina, despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening 4. Any planned surgery during the study which could be considered major in the opinion of the Investigator 5. History of more than 1 episode of severe hypoglycemia in the past 6 months. Severe hypoglycemia is defined as an event that requires the assistance of another person due to altered consciousness, and requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions. 6. History of more than 1 episode of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) in the past 6 months, unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis 7. Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement 8. Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of HbA1c 9. Plans to receive blood transfusion over the course of the 26-week trial phase. 10. Pregnant or lactating, or is of childbearing potential and not using an acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilization such as tubal ligation or hysterectomy, or vasectomized partner); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal). 11. Has taken systemic corticosteroids (oral or injectable) within 4 weeks or has had a local steroid injection (intraarticular, epidural) within 1 week prior to baseline CGM collection or plans to take oral or injectable steroids during the 26-week trial phase. 12. Participation in another clinical study using an investigational drug or device within prior 30 days or intends to participate in any other interventional study during the 26-week trial phase 13. Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment 14. Participant is an employee of Insulet, an Investigator or a member of Investigator's study team, or immediate family member of any of the aforementioned
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HbA1c | 15 and 26 weeks | Change in HbA1c (%) from baseline between the intervention and control groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean glucose | 15 and 26 weeks | Change in mean CGM glucose mg/dL from baseline, compared between the intervention and control groups |
| Time in Range 70-180 mg/dL | 15 and 26 weeks | Change in CGM percent time 70-180 mg/dL from baseline, compared between the intervention and control groups |
| Time > 180 mg/dL | 15 and 26 weeks | Change in CGM percent time \>180 mg/dL from baseline, compared between the intervention and control groups |
| Time > 250 mg/dL | 15 and 26 weeks | Change in CGM percent time \>250 mg/dL from baseline, compared between the intervention and control groups |
| Time in Range 70-140 mg/dL | 15 and 26 weeks | Change in CGM percent time 70-140 mg/dL from baseline, compared between the intervention and control groups |
| Prolonged hyperglycemia events per week | 15 and 26 weeks | Change in number of prolonged hyperglycemia events (\>90 minutes with a CGM glucose \>250 mg/dL within a 120 minute period) from baseline, compared between the intervention and control groups |
| Time <70 mg/dL | 15 and 26 weeks | Change in CGM percent time \<70 mg/dL from baseline, compared between the intervention and control groups |
| Time <54 mg/dL | 15 and 26 weeks | Change in CGM percent time \<54 mg/dL from baseline, compared between the intervention and control groups |
| Time >300 mg/dL | 15 and 26 weeks | Change in CGM percent time \>300 mg/dL from baseline, compared between the intervention and control groups |
| Type 2 Diabetes Distress Assessment System (T2-DDAS) | 15 and 26 weeks | — |
| Standard Deviation | 15 and 26 weeks | Change in standard deviation from baseline, compared between the intervention and control groups |
Countries
United States
Contacts
CONTACTTrang Ly, MBBS, PhD
CONTACTBonnie Dumais, RN
Outcome results
None listed